Katabolická dráha hemu u chronické hepatitidy C

• Název práce v češtině: Katabolická dráha hemu u chronické hepatitidy C
• Název v anglickém jazyce: The Heme Catabolic Pathway in Chronic Hepatitis C
• Klíčová slova: virus hepatitidy C, katabolická dráha hemu, hemoxygenáza, biliverdinreduktáza, UDP-glukuronosyltransferáza, genová exprese, genetické polymorfismy
• Klíčová slova anglicky: hepatitis C virus, heme catabolic pathway, heme oxygenase, biliverdin reductase, UDP-glucuronosyltransferase, gene expression, gene polymorphisms
• Akademický rok vypsání: 2012/2013
• Typ práce: disertační práce
• Jazyk práce: čeština
• Ústav: Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN (11-00410)
• Vedoucí / školitel: prof. MUDr. Tomáš Zima, DrSc., MBA
• Řešitel: skrytý - zadáno a potvrzeno stud. odd.
• Datum přihlášení: 11.06.2013
• Datum zadání: 11.06.2013
• Datum potvrzení stud. oddělením: 11.06.2013
• Datum a čas obhajoby: 26.09.2013 15:00
• Místo konání obhajoby: Děkanát 1. LF UK
• Datum odevzdání elektronické podoby: 12.06.2013
• Datum proběhlé obhajoby: 26.09.2013
• Předmět: Obhajoba dizertační práce (B90002)
• Oponenti: prof. MUDr. Richard Průša, CSc.

Seznam odborné literatury

1. Alberti A, Chemello L, Benvegnu L (1999) Natural history of hepatitis C. J Hepatol 31 Suppl 1: 17-24.
2. Seeff LB (1997) Natural history of hepatitis C. Hepatology 26: 21S-28S.
3. Roche B, Samuel D (2012) Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 32 Suppl 1: 120-128.
4.Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
5. Pawlotsky JM (2004) Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 12: 96-102.
6. Houghton M, editor (1996) Hepatitis C viruses. 3rd ed. Philadelphia: Lippincott-Raven. 1035-1058 p.
7. Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, et al. (2009) Genetic history of hepatitis C virus in East Asia. J Virol 83: 1071-1082.
8. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, et al. (1997) The origin of hepatitis C virus genotypes. J Gen Virol 78 ( Pt 2): 321-328.
9. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV (2001) Transfusion-associated hepatitis not due to viral hepatitis type A or B. 1975. Rev Med Virol 11: 3-8; discussion 8-9.
10. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.
11. Westaway EG (1987) Flavivirus replication strategy. Adv Virus Res 33: 45-90.
12. Robertson B, Myers G, Howard C, Brettin T, Bukh J, et al. (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143: 2493-2503.
13. Choi J, Ou JH (2006) Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 290: G847-851.
14. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
15. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, et al. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66: 3225-3229.
16. World Health Organization: Hepatitis C. World Health Organization Fact sheet 164 (Revised June 2011). Available:http://www.who.int/mediacentre/factsheets/fs164/en/.
17. Nemecek V, Strunecky O (2009) Genotypic heterogeneity of hepatitis C virus (HCV) from blood donors in the Czech Republic. Epidemiol Mikrobiol Imunol 58: 63-72.
18. Nemecek V, Castkova J, Fritz P, Linhartova A, Svandova E, et al. (2003) The 2001 serological survey in the Czech Republic-viral hepatitis. Cent Eur J Public Health 11 Suppl: S54-61.
19. Choo QL, Richman KH, Han JH, Berger K, Lee C, et al. (1991) Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 88: 2451-2455.
20. Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436: 933-938.
21. Bukh J, Purcell RH, Miller RH (1992) Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A 89: 4942-4946.
22. Brown EA, Zhang H, Ping LH, Lemon SM (1992) Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 20: 5041-5045.
23. Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A (1992) Internal ribosome entry site within hepatitis C virus RNA. J Virol 66: 1476-1483.
24. Kolykhalov AA, Feinstone SM, Rice CM (1996) Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J Virol 70: 3363-3371.
25. Tanaka T, Kato N, Cho MJ, Sugiyama K, Shimotohno K (1996) Structure of the 3' terminus of the hepatitis C virus genome. J Virol 70: 3307-3312.
26. Yanagi M, St Claire M, Emerson SU, Purcell RH, Bukh J (1999) In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci U S A 96: 2291-2295.
27. Dubuisson J (2007) Hepatitis C virus proteins. World J Gastroenterol 13: 2406-2415.
28. Bartenschlager R, Frese M, Pietschmann T (2004) Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63: 71-180.
29. Waris G, Tardif KD, Siddiqui A (2002) Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 64: 1425-1430.
30. Gale MJ, Jr., Korth MJ, Tang NM, Tan SL, Hopkins DA, et al. (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230: 217-227.
31. Gonzalez ME, Carrasco L (2003) Viroporins. FEBS Lett 552: 28-34.
32. Welsch C, Jesudian A, Zeuzem S, Jacobson I New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61 Suppl 1: i36-46.
33. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
34. Di Bisceglie AM, Hoofnagle JH (2002) Optimal therapy of hepatitis C. Hepatology 36: S121-127.
35. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. (1986) Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578.
36. Reichard O, Andersson J, Schvarcz R, Weiland O (1991) Ribavirin treatment for chronic hepatitis C. Lancet 337: 1058-1061.
37. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492.
38. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, et al. (1999) The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol 31: 407-415.
39. Malinoski F, Stollar V (1981) Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110: 281-289.
40. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR (2003) The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310: 333-342.
41. Tam RC, Pai B, Bard J, Lim C, Averett DR, et al. (1999) Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 30: 376-382.
42. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46: 1548-1563.
43. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, et al. (2003) Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 77: 5933-5947.
44. Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, et al. (2010) Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 139: 154-162 e154.
45. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53: 32-41.
46. Husa P, Plisek S, Sperl J, Urbanek P, Galsky J, et al. (2009) [Recommendations of the Society of Infectious Medicine, the Czech Hepatologic Society of the J.E. Purkinje Medical Society. Diagnosis and treatment of chronic hepatitis B]. Klin Mikrobiol Infekc Lek 15: 65-76.
47. Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, et al. (1999) Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 29: 904-907.
48. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, et al. (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34: 730-739.
49. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, et al. (2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357: 124-134.
50. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993-999.
51. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086-1097.
52. Jacobson IM, Brown RS, Jr., Freilich B, Afdhal N, Kwo PY, et al. (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971-981.
53. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, et al. (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433.
54. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
55. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
56. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, et al. (2004) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 24: 568-574.
57. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, et al. (2004) Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 99: 1733-1737.
58. Khuroo MS, Dahab ST (2004) Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 20: 931-938.
59. Lam KD, Trinh HN, Do ST, Nguyen TT, Garcia RT, et al. (2010) Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 52: 1573-1580.
60. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81.
61. Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, et al. (1999) Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 30: 1004-1013.
62. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, et al. (2004) Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53: 1345-1351.
63. Salmeron J, Casado J, Rueda PM, Lafuente V, Diago M, et al. (2008) Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. J Clin Virol 41: 264-269.
64. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, et al. (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 99: 3081-3086.
65. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, et al. (1995) Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 108: 789-795.
66. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, et al. (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288: 339-344.
67. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31: 211-218.
68. Bissell DM (1999) Sex and hepatic fibrosis. Hepatology 29: 988-989.
69. Urbanek P (2004) Infekce virem hepatitidy C: Galén.
70. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J (2002) Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97: 2408-2414.
71. Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639-644.
72. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, et al. (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30: 787-793.
73. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, et al. (2000) The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119: 1317-1323.
74. Brau N, Bini EJ, Currie S, Shen H, Schmidt WN, et al. (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. J Viral Hepat 13: 242-249.
75. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702-1708.
76. Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265-2271.
77. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477.
78. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419.
79. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, et al. (2006) Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 44: 1675-1684.
80. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38: 75-85.
81. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, et al. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33: 106-115.
82. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, et al. (2002) Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17: 873-881.
83. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, et al. (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358-1364.
84. Persico M, Persico E, Suozzo R, Conte S, De Seta M, et al. (2000) Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118: 760-764.
85. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609.
86. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, et al. (2005) Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522-527.
87. Bonkovsky HL, Banner BF, Rothman AL (1997) Iron and chronic viral hepatitis. Hepatology 25: 759-768.
88. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, et al. (1994) Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 20: 410-415.
89. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, et al. (2000) Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 32: 135-138.
90. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832.
91. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, et al. (2004) Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 40: 1018-1022.
92. Jorquera F, Monte MJ, Guerra J, Sanchez-Campos S, Merayo JA, et al. (2005) Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. J Gastroenterol Hepatol 20: 547-554.
93. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, et al. (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848.
94. Lecube A, Hernandez C, Simo R, Esteban JI, Genesca J (2007) Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol 102: 2189-2195.
95. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, et al. (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641.
96. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, et al. (2007) Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45: 80-87.
97. D'Souza R, Sabin CA, Foster GR (2005) Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100: 1509-1515.
98. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, et al. (2008) Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 48: 721-727.
99. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
100. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
101. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, et al. (2006) Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 131: 1440-1451.
102. Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP, et al. (2002) Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 22: 269-275.
103. Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, et al. (2004) Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 11: 175-182.
104. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, et al. (1995) Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108: 1104-1109.
105. Kageyama F, Kobayashi Y, Murohisa G, Shimizu E, Suzuki F, et al. (1998) Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Biol Trace Elem Res 64: 185-196.
106. Kaserer K, Exner M, Mosberger I, Penner E, Wrba F (1998) Characterization of the inflammatory infiltrate in autoimmune cholangitis. A morphological and immunhistochemical study. Virchows Arch 432: 217-222.
107. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, et al. (1996) Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 16: 248-254.
108. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, et al. (1997) Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 9: 497-503.
109. Barbaro G, Di Lorenzo G, Ribersani M, Soldini M, Giancaspro G, et al. (1999) Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 30: 774-782.
110. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, et al. (1996) Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 41: 989-994.
111. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, et al. (2001) Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33: 647-651.
112. Pietrangelo A (1998) Iron, oxidative stress and liver fibrogenesis. J Hepatol 28 Suppl 1: 8-13.
113. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, et al. (1998) Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27: 1695-1699.
114. Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ, Roman M, Hernandez-Bartolome A, et al. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Clin Pharmacol Ther 90: 712-721.
115. Sawhney R, Visvanathan K Polymorphisms of toll-like receptors and their pathways in viral hepatitis. Antivir Ther 16: 443-458.
116. Quaranta MG, Mattioli B, Vella S Glances in Immunology of HIV and HCV Infection. Adv Virol 2012: 434036.
117. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-1444.
118. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039.
119. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, et al. (2012) Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 142: 1122-1131 e1121.
120. Sixtos-Alonso MS, Sanchez-Munoz F, Sanchez-Avila JF, Martinez RA, Dominguez Lopez A, et al. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNalpha 2b and ribavirin in patients with hepatitis C virus genotype 1. Arch Med Res 42: 28-33.
121. Gerotto M, Dal Pero F, Bortoletto G, Realdon S, Ferrari A, et al. (2004) PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. Antivir Ther 9: 763-770.
122. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, et al. (2007) Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81: 3391-3401.
123. Huang C, Chen H, Cassidy W, Howell CD (2008) Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1. J Natl Med Assoc 100: 1425-1433.
124. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
125. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, et al. (2001) Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 120: 1438-1447.
126. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 54: 1094-1101.
127. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, et al. (1996) Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol 24: 271-276.
128. Pontisso P, Gerotto M, Benvegnu L, Chemello L, Alberti A (1998) Coinfection by hepatitis B virus and hepatitis C virus. Antivir Ther 3: 137-142.
129. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, et al. (2001) Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33: 240-247.
130. Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, et al. (2005) Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 128: 313-327.
131. Aster V, Machala L, Rozsypal H, Jilich D, Staňková M (2008) Problematika virových hepatitid u HIV infikovaných osob. Prakt Lék 88: 637-642.
132. Corrao G, Arico S (1998) Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27: 914-919.
133. Frieden TR, Ozick L, McCord C, Nainan OV, Workman S, et al. (1999) Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 29: 883-888.
134. Everhart J, Herion D (2000) Hepatitis C virus and alcohol.; Liang TJ, Hoofnagle HJ, editors. San Diego: Academic Press.
135. Romero-Gomez M, Grande L, Nogales MC, Fernandez M, Chavez M, et al. (2001) Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 33: 698-702.
136. Sherman KE, Rouster SD, Mendenhall C, Thee D (1999) Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 30: 265-270.
137. Mukaiya M, Nishi M, Miyake H, Hirata K (1998) Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology 45: 2328-2332.
138. Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, et al. (1994) The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 10: 657-664.
139. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, et al. (1998) Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27: 1717-1722.
140. Shull S, Heintz NH, Periasamy M, Manohar M, Janssen YM, et al. (1991) Differential regulation of antioxidant enzymes in response to oxidants. J Biol Chem 266: 24398-24403.
141. Halliwell J, Gutteridge JMC, (2007) Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death.; Halliwell J, Gutteridge JMC, editors. New York: Oxford University Press.
142. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA (2000) Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 28: 1456-1462.
143. Hodgson JM, Watts GF (2003) Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors 18: 129-136.
144. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, et al. (2001) L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276: 40-47.
145. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, et al. (2006) Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 80: 7199-7207.
146. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG (1994) Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A 91: 5987-5991.
147. Buettner GR, Jurkiewicz BA (1996) Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145: 532-541.
148. Štípek S., al. (2000) Antioxidanty a volné radikály ve zdraví a v nemoci. Praha: Grada.
149. McCord JM (2000) The evolution of free radicals and oxidative stress. Am J Med 108: 652-659.
150. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, et al. (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122: 366-375.
151. Mottola G, Cardinali G, Ceccacci A, Trozzi C, Bartholomew L, et al. (2002) Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 293: 31-43.
152. Pahl HL (1999) Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol Rev 79: 683-701.
153. Murphy AN, Bredesen DE, Cortopassi G, Wang E, Fiskum G (1996) Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci U S A 93: 9893-9898.
154. Tardif KD, Waris G, Siddiqui A (2005) Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 13: 159-163.
155. Gong G, Waris G, Tanveer R, Siddiqui A (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 98: 9599-9604.
156. Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan BE (2005) Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 76: 489-497.
157. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, et al. (2004) Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal 6: 19-24.
158. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, et al. (2001) Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem 276: 23077-23083.
159. Thoren F, Romero A, Lindh M, Dahlgren C, Hellstrand K (2004) A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. J Leukoc Biol 76: 1180-1186.
160. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, et al. (2001) Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61: 4365-4370.
161. Forman HJ, Torres M, Fukuto J (2003) Signal Transduction by Reactive Oxygen and Nitrogen Species: Pathways and Chemical Principles. Boston: Kluwer Academic.
162. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, et al. (2005) Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 86: 2185-2196.
163. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, et al. (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280: 37481-37488.
164. Rockey DC (2000) The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications. Clin Liver Dis 4: 319-355.
165. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, et al. (2004) Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126: 586-597.
166. Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21: 49-98.
167. Waris G, Siddiqui A (2005) Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 79: 9725-9734.
168. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. Cell 98: 295-303.
169. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, et al. (2004) Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39: 81-89.
170. Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, et al. (2004) Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. J Virol 78: 8835-8843.
171. Evans JL, Maddux BA, Goldfine ID (2005) The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 7: 1040-1052.
172. Knobler H, Schattner A (2005) TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 98: 1-6.
173. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, et al. (2005) Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 39: 737-742.
174. Ko WS, Guo CH, Yeh MS, Lin LY, Hsu GS, et al. (2005) Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J Gastroenterol 11: 4697-4702.
175. Tenhunen R, Marver HS, Schmid R (1968) The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 61: 748-755.
176. Maines MD (1997) The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554.
177. Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, et al. (2004) Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Free Radic Biol Med 37: 146-155.
178. Willis D, Moore AR, Frederick R, Willoughby DA (1996) Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 2: 87-90.
179. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH (1993) Carbon monoxide: a putative neural messenger. Science 259: 381-384.
180. Baranano DE, Rao M, Ferris CD, Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 99: 16093-16098.
181. Vitek L, Schwertner HA (2007) The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 43: 1-57.
182. Vitek L, Ostrow JD (2009) Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 15: 2869-2883.
183. Liu XM, Chapman GB, Peyton KJ, Schafer AI, Durante W (2003) Antiapoptotic action of carbon monoxide on cultured vascular smooth muscle cells. Exp Biol Med (Maywood) 228: 572-575.
184. Ryter SW, Otterbein LE, Morse D, Choi AM (2002) Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem 234-235: 249-263.
185. Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ, et al. (1998) Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo. Circ Res 83: 568-577.
186. Goda N, Suzuki K, Naito M, Takeoka S, Tsuchida E, et al. (1998) Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. J Clin Invest 101: 604-612.
187. Li L, Grenard P, Nhieu JT, Julien B, Mallat A, et al. (2003) Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 125: 460-469.
188. Yachie A, Toma T, Mizuno K, Okamoto H, Shimura S, et al. (2003) Heme oxygenase-1 production by peripheral blood monocytes during acute inflammatory illnesses of children. Exp Biol Med (Maywood) 228: 550-556.
189. Zhu Z, Wilson AT, Mathahs MM, Wen F, Brown KE, et al. (2008) Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 48: 1430-1439.
190. Abdalla MY, Britigan BE, Wen F, Icardi M, McCormick ML, et al. (2004) Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis 190: 1109-1118.
191. Wen F, Brown KE, Britigan BE, Schmidt WN (2008) Hepatitis C core protein inhibits induction of heme oxygenase-1 and sensitizes hepatocytes to cytotoxicity. Cell Biol Toxicol 24: 175-188.
192. Ghaziani T, Shan Y, Lambrecht RW, Donohue SE, Pietschmann T, et al. (2006) HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol 45: 5-12.
193. Lin JP, Vitek L, Schwertner HA Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 56: 1535-1543.
194. Yamaguchi T, Komoda Y, Nakajima H (1994) Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem 269: 24343-24348.
195. Pereira PJ, Macedo-Ribeiro S, Parraga A, Perez-Luque R, Cunningham O, et al. (2001) Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol 8: 215-220.
196. Maines MD (2010) Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings. Curr Drug Targets 11: 1586-1594.
197. Maines MD, Mayer RD, Erturk E, Huang TJ, Disantagnese A (1999) The oxidoreductase, biliverdin reductase, is induced in human renal carcinoma--pH and cofactor-specific increase in activity. J Urol 162: 1467-1472.
198. Goven D, Boutten A, Lecon-Malas V, Marchal-Somme J, Soler P, et al. (2010) Induction of heme oxygenase-1, biliverdin reductase and H-ferritin in lung macrophage in smokers with primary spontaneous pneumothorax: role of HIF-1alpha. PLoS One 5: e10886.
199. Mueller C, Zhou W, Vanmeter A, Heiby M, Magaki S, et al. (2010) The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. J Alzheimers Dis 19: 1081-1091.
200. Miralem T, Hu Z, Torno MD, Lelli KM, Maines MD (2005) Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J Biol Chem 280: 17084-17092.
201. Florczyk UM, Jozkowicz A, Dulak J (2008) Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol Rep 60: 38-48.
202. Tudor C, Lerner-Marmarosh N, Engelborghs Y, Gibbs PE, Maines MD (2008) Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem J 413: 405-416.
203. Ahmad Z, Salim M, Maines MD (2002) Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress. J Biol Chem 277: 9226-9232.
204. Kravets A, Hu Z, Miralem T, Torno MD, Maines MD (2004) Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J Biol Chem 279: 19916-19923.
205. Ding B, Gibbs PE, Brookes PS, Maines MD (2011) The coordinated increased expression of biliverdin reductase and heme oxygenase-2 promotes cardiomyocyte survival: a reductase-based peptide counters beta-adrenergic receptor ligand-mediated cardiac dysfunction. FASEB J 25: 301-313.
206. Pawson T, Scott JD (2005) Protein phosphorylation in signaling--50 years and counting. Trends Biochem Sci 30: 286-290.
207. Kapitulnik J, Maines MD (2009) Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 30: 129-137.
208. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, et al. (2004) Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J 378: 919-928.
209. Lin R, Wang Y, Fu W, Zhang D, Zheng H, et al. (2009) Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics 19: 310-318.
210. Goswami R, Sutton BS, Rouf C, Nelson S, Haynes C, et al. (2008) Biliverdin Reductase Genetic Polymorphisms are Associated with Early-Onset Coronary Artery Disease In Two Datasets. Circulation 118: S389-S390.
211. Lin R, Wang X, Wang Y, Zhang F, Fu W, et al. (2009) Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations. Hum Mutat 30: 609-615.
212. Gafvels M, Holmstrom P, Somell A, Sjovall F, Svensson JO, et al. (2009) A novel mutation in the biliverdin reductase-A gene combined with liver cirrhosis results in hyperbiliverdinaemia (green jaundice). Liver Int 29: 1116-1124.
213. Nytofte NS, Serrano MA, Monte MJ, Gonzalez-Sanchez E, Tumer Z, et al. (2011) A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. J Med Genet 48: 219-225.
214. Maines MD (2005) New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 20: 382-389.
215. Nakagami T, Taji S, Takahashi M, Yamanishi K (1992) Antiviral activity of a bile pigment, biliverdin, against human herpesvirus 6 (HHV-6) in vitro. Microbiol Immunol 36: 381-390.
216. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, et al. (1991) Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51: 6656-6659.
217. Lehmann E, El-Tantawy WH, Ocker M, Bartenschlager R, Lohmann V, et al. (2010) The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology 51: 398-404.
218. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
219. Urbanek P, Husa P, Galsky J, Sperl J, Kumpel P, et al. (2008) [Standard diagnostic and therapeutic approach to the chronic infection with hepatitis C (HCV) virus]. Cas Lek Cesk 147: I-XII.
220. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
221. Vreman HJ, Stevenson DK (1988) Detection of heme oxygenase activity by measurement of CO In: Maines MD, Costa LG, Reed DJ, Sassa S, Sipes IG, editors. Current Protocols in Toxicology New York: John Wiley&Sons. pp. Unit 9.2.1-9.2.10.
222. Carriere M, Pene V, Breiman A, Conti F, Chouzenoux S, et al. (2007) A novel, sensitive, and specific RT-PCR technique for quantitation of hepatitis C virus replication. J Med Virol 79: 155-160.
223. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
224. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
225. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
226. Jiraskova A, Novotny J, Novotny L, Vodicka P, Pardini B, et al. Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer. Int J Cancer 131: 1549-1555.
227. Urbanek P (2011) Závěrečná zpráva o řešení grantového projektu IGA MZ ČR NR 9412-3/2007.
228. Urbanek P, Subhanova I, Janousova E, Dusek L, Marecek Z, et al. (2009) [Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV]. Vnitr Lek 55: 474-479.
229. Peterhans E (1997) Reactive oxygen species and nitric oxide in viral diseases. Biol Trace Elem Res 56: 107-116.
230. Lieber CS (1997) Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv Pharmacol 38: 601-628.
231. Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, et al. (2005) rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology 42: 335-342.
232. Jiraskova A, Lenicek M, Vitek L Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes using multicolored capillary electrophoresis. Clin Biochem 43: 697-699.
233. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, et al. (2000) Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 66: 187-195.
234. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-264.
235. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, et al. (2009) Gene expression and hepatitis C virus infection. Gut 58: 846-858.
236. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-129
237. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 33: 1162-1172.
238. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
239. Frankova S, Bartakova R, Hejda V, Urbanek P, Husova L, et al. (2012) IL28 rs 12979860 CC genotype slows progression of liver disease in HCV infected patients. Gastroenterologie a Hepatologie 66: S17.
240. Schmitz G, Dotzauer A (1998) Proof of hepatitis A virus negative-sense RNA by RNA/DNA-hybrid detection: a method for specific detection of both viral negative- and positive-strand RNA species. Nucleic Acids Res 26: 5230-5232.
241. Kao JH, Chen PJ, Lai MY, Wang TH, Chen DS (1997) Positive and negative strand of hepatitis C virus RNA sequences in peripheral blood mononuclear cells in patients with chronic hepatitis C: no correlation with viral genotypes 1b, 2a, and 2b. J Med Virol 52: 270-274.
242. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, et al. (2006) Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130: 1107-1116.
243. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, et al. (2006) Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 43: 961-972.
244. He XS, Ji X, Hale MB, Cheung R, Ahmed A, et al. (2006) Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44: 352-359.
245. Kwo PY (2013) Boceprevir and treatment of chronic hepatitis C. Clin Liver Dis 17: 63-72.
246. Maddur H, Kwo PY (2011) Boceprevir. Hepatology 54: 2254-2257.
247. Niepmann N (2009) Internal translation initiation of picornaviruses and hepatitis C virus. In: Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1789: 529-541.
248. Moradpour D, Penin F, Rice CM (2007) Nature Reviews Microbiology 5:453-463.
249.Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y et al. (2004) Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin 25: 977-985.
250.Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL (2006) Mechanisms of disease:
mitochondria as new therapeutic targets in diabetic neuropathy.Nat Clin Pract Neurol
2: 620-8.
251.De Giorgi V, Buonaguro L, Worschech A, Tornesello ML, Izzo F, et al. (2013)
Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and
Liver Metastasis. PLoS ONE 8(2): e56153.